AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34769736 — intervention group
Group type: COMPARATOR
Intervention: Control group (received training at the end of the study)
Number of subjects: 60
Study 34769736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (received ergonomic training)
Number of subjects: 60
Study 32937032 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medication use
Number of subjects: 873
Study 32937032 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 873
Study 32937032 — intervention group
Group type: COMPARATOR
Intervention: Adjustment disorders
Number of subjects: 873
Study 32672653 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Peripheral Iridotomy (LPI)
Number of subjects: 455
Study 36441137 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac (Lot 1)
Number of subjects: 1080
Study 36441137 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac (Lot 2)
Number of subjects: 1080
Study 36441137 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac (Lot 3)
Number of subjects: 1080
Study 34837974 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention (CBI)
Number of subjects: 3927
Study 34837974 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3927
Study 36158805 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician led enteral feeding
Number of subjects: 0
Study 36158805 — intervention group
Group type: COMPARATOR
Intervention: Protocol‐based feeding group
Number of subjects: 0
Study 32282492 — intervention group
Group type: EXPERIMENTAL
Intervention: Magic Empowerment Program (3 workshops on 3 successive days, followed by weekly phone calls for 8 weeks)
Number of subjects: 84
Study 32282492 — intervention group
Group type: EXPERIMENTAL
Intervention: Magic Empowerment Program
Number of subjects: 84
Study 32282492 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 84
Study 34969608 — intervention group
Group type: EXPERIMENTAL
Intervention: Zataria‐Trachyspermum (ZT) capsule
Number of subjects: 150
Study 34969608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 34969608 — intervention group
Group type: COMPARATOR
Intervention: Mebeverine capsule
Number of subjects: 150
Study 32386810 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 785
Study 32386810 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification cataract surgery (PCS)
Number of subjects: 785
Study 33926535 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist palliative care intervention
Number of subjects: 236
Study 33926535 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 236
Study 34213586 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee Control high-dose group (≥2 sessions)
Number of subjects: 301
Study 34213586 — intervention group
Group type: COMPARATOR
Intervention: Knee Control low-dose group (<1 session)
Number of subjects: 301
Study 34550413 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching unit for primary and secondary prevention of unplanned pregnancies
Number of subjects: 1855
Study 35411460 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 230
Study 35411460 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-BLI
Number of subjects: 230
Study 35411460 — intervention group
Group type: EXPERIMENTAL
Intervention: LED-BLI
Number of subjects: 230
Study 33666156 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 29
Study 33666156 — intervention group
Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 29
Study 34032758 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Engagement and Medication Safety Management (PE‐MSM) program
Number of subjects: 120
Study 34032758 — intervention group
Group type: COMPARATOR
Intervention: Medication safety education alone
Number of subjects: 120
Study 35797618 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal irrigation (TAI)
Number of subjects: 45
Study 35797618 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (control)
Number of subjects: 45
Study 34620531 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccine
Number of subjects: 1620
Study 34620531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1620
Study 32453647 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime ultra-rapid lispro (URLi)
Number of subjects: 269
Study 32453647 — intervention group
Group type: COMPARATOR
Intervention: Postmeal ultra-rapid lispro (URLi)
Number of subjects: 269
Study 32453647 — intervention group
Group type: COMPARATOR
Intervention: Mealtime lispro
Number of subjects: 269
Study 36145214 — intervention group
Group type: EXPERIMENTAL
Intervention: Course for patients and nurses (CPN group)
Number of subjects: 119
Study 36145214 — intervention group
Group type: COMPARATOR
Intervention: No course for patients and nurses (non-C group)
Number of subjects: 119
Study 36145214 — intervention group
Group type: EXPERIMENTAL
Intervention: Course for nurses (CN group)
Number of subjects: 119
Study 36145214 — intervention group
Group type: EXPERIMENTAL
Intervention: Course for patients (CP group)
Number of subjects: 119
Study 33686520 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Skills Training (CST)
Number of subjects: 31
Study 33686520 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 31
Study 32249651 — intervention group
Group type: EXPERIMENTAL
Intervention: Monique Burr Foundation's Child Safety Matters curriculum
Number of subjects: 1176
Study 32249651 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 1176
Study 32276883 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone at 3.5 mg kgâ€“1
Number of subjects: 66
Study 32276883 — intervention group
Group type: COMPARATOR
Intervention: Alfaxalone 2 mg kgâ€“1 and medetomidine 40 Î¼g kgâ€“1, reversed with atipamezole at 0.16 mg kgâ€“1
Number of subjects: 66
Study 35623880 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium breakfast from calcium citrate (∼770 mg/d)
Number of subjects: 35
Study 35623880 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium breakfast from skim milk (∼770 mg/d)
Number of subjects: 35
Study 35623880 — intervention group
Group type: COMPARATOR
Intervention: Low calcium breakfast (control, ∼70 mg of calcium/d)
Number of subjects: 35
Study 34858506 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Acupuncture (BA)
Number of subjects: 60
Study 34858506 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 60
Study 34858506 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + Cupping (CA)
Number of subjects: 60
Study 33268715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice cream with azithromycin
Number of subjects: 16
Study 33268715 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt with carbocysteine
Number of subjects: 16
Study 36108265 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion (RME)
Number of subjects: 34
Study 36108265 — intervention group
Group type: COMPARATOR
Intervention: Slow Maxillary Expansion (SME)
Number of subjects: 34
Study 34774348 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01% eye drops (1 drop/day for 2 years)
Number of subjects: 339
Study 34774348 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 339
Study 32042166 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 309
Study 32042166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 35505362 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO‐EMRO School Mental Health Manual based Intervention
Number of subjects: 231
Study 35505362 — intervention group
Group type: COMPARATOR
Intervention: Wait list delayed intervention control group
Number of subjects: 231
Study 32506456 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional treatment (transjugular thrombus fragmentation, local thrombolysis with or without stent implantation)
Number of subjects: 65
Study 32506456 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 65
Study 34501630 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to varied neighborhood contexts (including neighborhood socioeconomic status, older housing stock, residential instability, and prevalence of neurological hazards in the ambient air)
Number of subjects: 590
Study 34228102 — intervention group
Group type: EXPERIMENTAL
Intervention: IV zoledronic acid (ZA) 0.05 mg/kg
Number of subjects: 34
Study 34228102 — intervention group
Group type: COMPARATOR
Intervention: IV placebo
Number of subjects: 34
Study 34228102 — intervention group
Group type: EXPERIMENTAL
Intervention: IV zoledronic acid (ZA)
Number of subjects: 34
Study 32325491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mature neutrophils at diagnosis
Number of subjects: 267
Study 32325491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mature neutrophils
Number of subjects: 267
Study 32325491 — intervention group
Group type: EXPERIMENTAL
Intervention: Depletion of mature neutrophils
Number of subjects: 267
Study 35024932 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater cold snare polypectomy (U-CSP)
Number of subjects: 110
Study 35024932 — intervention group
Group type: COMPARATOR
Intervention: Conventional cold snare polypectomy (C-CSP)
Number of subjects: 110
Study 34231351 — intervention group
Group type: EXPERIMENTAL
Intervention: CMO pharmaceutical care model-based intervention
Number of subjects: 39
Study 34231351 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 39
Study 32342893 — intervention group
Group type: EXPERIMENTAL
Intervention: Seat pan angle of 40° and backrest angle of 155°
Number of subjects: 23
Study 32342893 — intervention group
Group type: EXPERIMENTAL
Intervention: Seat pan angles of 20°, 30°, 40° and backrest angles of 145°, 155°, 165°
Number of subjects: 23
Study 32342893 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 165° backrest angle with a seat pan of 20°
Number of subjects: 23
Study 32191071 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking with health goal (EFT-health goal)
Number of subjects: 444
Study 32191071 — intervention group
Group type: COMPARATOR
Intervention: Episodic Future Thinking without health goal (EFT-general)
Number of subjects: 444
Study 32191071 — intervention group
Group type: COMPARATOR
Intervention: Episodic Recent Thinking with health goal (ERT-health goal)
Number of subjects: 444
Study 32191071 — intervention group
Group type: COMPARATOR
Intervention: Episodic Recent Thinking without health goal (ERT-general)
Number of subjects: 444
Study 32282255 — intervention group
Group type: EXPERIMENTAL
Intervention: PFMT+KT
Number of subjects: 0
Study 32282255 — intervention group
Group type: COMPARATOR
Intervention: PFMT+ST
Number of subjects: 0
Study 32979708 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean (Soygan 500 mg capsule)
Number of subjects: 180
Study 32979708 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (Omega-rex 1000 mg soft gel)
Number of subjects: 180
Study 32979708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 35218203 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 385
Study 35218203 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 385
Study 35218203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study 34026336 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Docetaxel (GD)
Number of subjects: 237
Study 34026336 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 237
Study 35737597 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide 600 mg plus lithium and risperidone 3 mg
Number of subjects: 63
Study 35737597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 34139228 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram developed using CT parameters
Number of subjects: 1001
Study 32015513 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC)
Number of subjects: 488
Study 34714125 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care with mother's own milk (MOM)
Number of subjects: 110
Study 32772215 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF plus CMX
Number of subjects: 24
Study 32772215 — intervention group
Group type: COMPARATOR
Intervention: CAF alone
Number of subjects: 24
Study 35363574 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-day multipurpose prevention technology (MPT) intravaginal ring (IVR)
Number of subjects: 47
Study 33783495 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined ART care (rapid ART start, visit spacing, flexible clinic hours, welcoming environment)
Number of subjects: 13266
Study 33783495 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined ART care
Number of subjects: 13266
Study 33783495 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment model)
Number of subjects: 13266
Study 35413022 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection (defined as COVID-19 clinical diagnosis or presence of SARS-CoV-2 IgG/IgA antibodies)
Number of subjects: 2464
Study 35413022 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic SARS-CoV-2 infection
Number of subjects: 2464
Study 35413022 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic COVID-19
Number of subjects: 2464
Study 35413022 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 counts and HIV viral suppression rates
Number of subjects: 2464
Study 33705167 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular cognitive behavioral therapy (CBT)
Number of subjects: 107
Study 33705167 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard community treatment (ESCT)
Number of subjects: 107
Study 32033527 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU/week for 8 weeks)
Number of subjects: 90
Study 32033527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 33441831 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptomic analysis of female P. edita
Number of subjects: 0
Study 33441831 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptomic analysis of male P. edita
Number of subjects: 0
Study 33441831 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of transcriptomic data by qRT‐PCR
Number of subjects: 0
Study 33441831 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of simple sequence repeats (SSRs)
Number of subjects: 0
Study 33441831 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative analysis of sex-related genes and pathways
Number of subjects: 0
Study 33021870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib
Number of subjects: 706
Study 33021870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 706
Study 35225460 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml ONS twice a day
Number of subjects: 58
Study 35225460 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 58
Study 32660299 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive low-dose transdermal testosterone cream
Number of subjects: 101
Study 32660299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 35833539 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine‐derived collagenated xenogeneic bone blocks (CXBB)
Number of subjects: 64
Study 35833539 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone block (ABB)
Number of subjects: 64
Study 34980307 — intervention group
Group type: EXPERIMENTAL
Intervention: Early off-bed mobility (using shift machine, off-bed sitting, and walking aids)
Number of subjects: 266
Study 34980307 — intervention group
Group type: EXPERIMENTAL
Intervention: Early off-bed mobility
Number of subjects: 266
Study 36301169 — intervention group
Group type: EXPERIMENTAL
Intervention: DCKEBS+acupuncture
Number of subjects: 147
Study 36301169 — intervention group
Group type: COMPARATOR
Intervention: DCKEBS
Number of subjects: 147
Study 36301169 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 147
Study 34535548 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine with 5 mg dexamethasone
Number of subjects: 0
Study 34535548 — intervention group
Group type: COMPARATOR
Intervention: 0.5% ropivacaine (control)
Number of subjects: 0
Study 36166273 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based program to improve physical activity (PA) over 3 months
Number of subjects: 59
Study 34198131 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (2-mg lozenge)
Number of subjects: 17
Study 34198131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 33264172 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial appendage occlusion (LAAO)
Number of subjects: 0
Study 616521239 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE and bevacizumab
Number of subjects: 22
Study 616521239 — intervention group
Group type: COMPARATOR
Intervention: TACE and placebo
Number of subjects: 22
Study 34352069 — intervention group
Group type: EXPERIMENTAL
Intervention: filgotinib 200 mg once daily for 12 weeks
Number of subjects: 116
Study 34352069 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 116
Study 33148476 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Ankle Replacement (TAA)
Number of subjects: 39
Study 33148476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle Arthrodesis (AA)
Number of subjects: 39
Study 36178832 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-delivered one-on-one feedback to GPs and electronic tick-box for GPs to select action for each patient.
Number of subjects: 39
Study 36178832 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement with GPs in the intervention group.
Number of subjects: 39
Study 36178832 — intervention group
Group type: EXPERIMENTAL
Intervention: Sending letters to patients with high-risk prescribing.
Number of subjects: 39
Study 36178832 — intervention group
Group type: EXPERIMENTAL
Intervention: General engagement and participation in the trial.
Number of subjects: 39
Study 33704969 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-focused literacy intervention (Reach Out and Read)
Number of subjects: 38
Study 33704969 — intervention group
Group type: COMPARATOR
Intervention: Baseline (preintervention) measurements
Number of subjects: 38
Study 35473436 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening performance (19:00 h)
Number of subjects: 15
Study 35473436 — intervention group
Group type: COMPARATOR
Intervention: Morning performance (9:00 h)
Number of subjects: 15
Study 35473436 — intervention group
Group type: COMPARATOR
Intervention: Chronotype
Number of subjects: 15
Study 32679839 — intervention group
Group type: EXPERIMENTAL
Intervention: Forest video
Number of subjects: 0
Study 32679839 — intervention group
Group type: COMPARATOR
Intervention: Urban video (Control)
Number of subjects: 0
Study 33271604 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnose-and-leave-in strategy for diminutive rectosigmoid polyps
Number of subjects: 256
Study 33693653 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with PCOS
Number of subjects: 9508
Study 33693653 — intervention group
Group type: COMPARATOR
Intervention: Women without PCOS
Number of subjects: 9508
Study 33693653 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women with PCOS
Number of subjects: 9508
Study 33693653 — intervention group
Group type: COMPARATOR
Intervention: Lean women with PCOS
Number of subjects: 9508
Study 32787371 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective anticoagulation group (SAG)
Number of subjects: 197
Study 32787371 — intervention group
Group type: COMPARATOR
Intervention: Conventional anticoagulation group (CAG)
Number of subjects: 197
Study 34308903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 130
Study 34308903 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 130
Study 34308903 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 130
Study 32285979 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg)
Number of subjects: 255
Study 32285979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 34019513 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment of migraine headaches
Number of subjects: 0
Study 615261596 — intervention group
Group type: EXPERIMENTAL
Intervention: anodal tDCS
Number of subjects: 14
Study 615261596 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 14
Study 34245336 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab + docetaxel
Number of subjects: 86
Study 34245336 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab
Number of subjects: 86
Study 34245336 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab
Number of subjects: 86
Study 34758056 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) compound filling plus mesotherapy
Number of subjects: 48
Study 34758056 — intervention group
Group type: COMPARATOR
Intervention: Botulinum Toxin A (BTX-A) injection
Number of subjects: 48
Study 34508021 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based lumbar disc surgery discharge training
Number of subjects: 60
Study 34508021 — intervention group
Group type: COMPARATOR
Intervention: Routine discharge training in the ward (Control)
Number of subjects: 60
Study 36484803 — intervention group
Group type: EXPERIMENTAL
Intervention: Test methotrexate tablet (2.5 mg) under fasting conditions
Number of subjects: 52
Study 36484803 — intervention group
Group type: COMPARATOR
Intervention: Reference methotrexate tablet (2.5 mg) under fed conditions
Number of subjects: 52
Study 36484803 — intervention group
Group type: EXPERIMENTAL
Intervention: Test and reference methotrexate tablets (2.5 mg)
Number of subjects: 52
Study 33203966 — intervention group
Group type: EXPERIMENTAL
Intervention: AACQ
Number of subjects: 264
Study 33203966 — intervention group
Group type: COMPARATOR
Intervention: TQ
Number of subjects: 264